• Vaccine Name: ALVAC-AHSV
• Target Pathogen: African horse sickness virus
• Vaccine Ontology ID: VO_0004725
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: Baboon
• Vector:
  • Vector name:
  • VO vector ID: VO_0001128
• Preparation: Recombinant canarypox virus vector (ALVAC-AHSV) co-expressing synthetic genes encoding the outer capsid proteins (VP2 and VP5) of AHSV serotype 4 (AHSV-4) (Guthrie et al., 2009).
• Immunization Route: Intramuscular injection (i.m.)

Horse Response

• Vaccination Protocol: Two groups of four horses each (two males and two females) were inoculated intramuscularly with 10^7.1 or 10^6.4 TCID50, respectively, of ALVAC–AHSV in approximately 1 ml of diluent containing a Carbopol® 974P adjuvant (BF Goodrich) (Guthrie et al., 2009).
• Vaccine Immune Response Type: VO_0003057
• Challenge Protocol: All nine horses were challenged by intravenous inoculation of 105.5 TCID50 of AHSV-4 at 28 days after the second vaccination (week 8) (Guthrie et al., 2009).
• Efficacy: Post challenge, all horses remained healthy and showed no adverse effects after vaccination (Guthrie et al., 2009).